Novonesis has unveiled its ‘GROW’ strategy and long-term targets until 2030, aiming for an organic sales CAGR of 6-9%, an adjusted EBITDA margin of ~39%, and an adjusted ROIC excl. goodwill of ~16%. The company’s focus on biosolutions is driven by global demand for tailored solutions in various industries. Novonesis’ growth matrix includes volume growth, pricing strategies, and market expansion. New explorative areas include Biopharma Processing Aids, Future Fuels and Chemicals, and Specialized Nutrition Proteins. The company plans to present its 2030 strategy during the H1 2025 conference call on August 21.

Read more at GlobeNewswire: 2030 financial targets announced: Organic sales growth